Welcome to our dedicated page for NewAmsterdam Pharma Co N.V. SEC filings (Ticker: NAMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on NewAmsterdam Pharma Co N.V.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into NewAmsterdam Pharma Co N.V.'s regulatory disclosures and financial reporting.
NewAmsterdam Pharma Co N.V. (NAMS) reported that Vice President, Controller Robert William Gunning received equity compensation awards on September 1, 2026. He was granted options for 14,000 ordinary shares at an exercise price of $24.92 per share, expiring August 31, 2036, plus 3,200 restricted stock units, each representing one ordinary share. The RSUs vest in three equal annual installments beginning September 10, 2026, and 25% of the option shares vest on August 10, 2026, with the remainder vesting in equal monthly installments over the following three years, in each case subject to his continued service. No Rule 10b5-1 trading plan is reported.
NewAmsterdam Pharma Co N.V. (NAMS) is the issuer of ordinary shares that an affiliate, for the account of Kastelein Johannes Jacob Pieter, plans to sell under Rule 144. A notice covers up to 250,000 ordinary shares, with J.P. Morgan Securities LLC acting as broker on Nasdaq.
The filing states these shares are expected to be sold in the next 90 days by Futurum B.V., where John Kastelein is a director. The shares relate to an option exercise from the issuer on 08/24/2026, for cash consideration. Reported outstanding ordinary shares total 119,537,169.
NewAmsterdam Pharma Co N.V. (NAMS) reports that Chief Scientific Officer Johannes Jacob Pieter Kastelein, through Futurum B.V. and NAP PoolCo B.V., exercised options for 125,000 Ordinary Shares and on the same day sold 125,000 Ordinary Shares at a weighted average price of $26.91 per share. The options had an exercise price of EUR 1.16392 per share and were held indirectly through Futurum/PoolCo. After these transactions, Kastelein continues to hold 395,229 options indirectly and 53,500 Ordinary Shares directly, including 48,166 shares subject to RSU vesting. All reported trades were executed under a Rule 10b5-1 trading plan adopted by Futurum B.V. on March 31, 2026.
NewAmsterdam Pharma Co N.V. (NAMS) is named as the issuer in a notice of proposed sale of restricted or control securities under Form 144. An affiliate associated with Johannes Jacob Pieter Kastelein, with sales expected by Futurum B.V., has filed to potentially sell up to 125,000 Ordinary Shares through J.P. Morgan Securities LLC on Nasdaq.
The filing lists an aggregate market value of 3,483,750 for these shares and states that 119,537,169 Ordinary Shares were outstanding. The approximate date of sale is given as 08/24/2026, with the shares acquired via option exercise for cash from the issuer and expected to be sold within the next 90 days.
NewAmsterdam Pharma Company N.V. filed an amendment detailing the final terms of separation and advisory agreements with former Chief Operating Officer Douglas Kling, who resigned effective August 14, 2026 to become chief executive officer of another clinical-stage biotech company. Under a letter separation agreement with a subsidiary, Kling’s unvested stock options and restricted stock units as of the separation date are canceled, except for portions that vest solely based on continued service through May 14, 2027, which may continue to vest while he serves as an advisor. The agreement also includes confidentiality, non-disparagement, non-solicitation covenants, and a release of claims. A separate advisor agreement with another subsidiary provides that Kling will deliver transition and advisory services related to the PREVAIL clinical trial of obicetrapib and other programs for a $50,000 monthly service fee plus reimbursable expenses, through May 14, 2027 unless terminated earlier.
NewAmsterdam Pharma Co N.V. reported that Robert William Gunning, who serves as Vice President, Controller, filed an initial statement of beneficial ownership on Form 3. The filing lists no reportable equity transactions or holdings at this time.
NewAmsterdam Pharma Company N.V. appointed Robert W. Gunning, 55, as principal accounting officer effective August 10, 2026, succeeding Louise Kooij, whose departure effective August 31, 2026 had been previously announced. Gunning joined as Vice President, Controller on the same date, bringing prior senior finance and controller experience at several biopharmaceutical and biotechnology companies.
Under a July 24, 2026 offer letter with a wholly owned subsidiary, Gunning will receive a $375,000 annual base salary and be eligible for an annual performance bonus targeted at 30% of base salary, prorated for his first year and subject to board discretion. He will also be granted 3,200 restricted stock units and a stock option to purchase 14,000 ordinary shares under the 2024 Inducement Plan. The company states he has no disclosable related-party relationships or material interests in company transactions beyond standard indemnification arrangements.
FMR LLC and Abigail P. Johnson report a significant ownership position in PHARMA COMPANY NV. They beneficially own 10,339,663 shares of common stock, representing 8.8% of the class, based on information as of June 30, 2026.
FMR LLC has sole voting power over 10,329,760 shares and sole dispositive power over 10,339,663 shares, with no shared voting or dispositive power. Abigail P. Johnson is reported with sole dispositive power over the same 10,339,663 shares and no voting power, reflecting her position related to FMR LLC and its subsidiaries. One or more other persons have rights to receive dividends or sale proceeds from these shares, but no such person holds more than five percent of the outstanding common stock.
NewAmsterdam Pharma Company N.V. reported results for the quarter ended June 30, 2026 and highlighted regulatory and clinical developments. The Committee for Medicinal Products for Human Use issued a positive opinion recommending EU marketing authorization for obicetrapib (Ubeslo) and the obicetrapib/ezetimibe fixed-dose combination (Evlarco), with a European Commission decision expected later this year.
The company is running multiple Phase 3 programs, including the PREVAIL cardiovascular outcomes trial with over 9,500 patients enrolled and an interim analysis planned for the fourth quarter of 2026, the REMBRANDT imaging trial with 323 patients enrolled, and the RUBENS diabetes/metabolic syndrome trial targeting about 300 patients and topline data by year-end 2026. Cash, cash equivalents and marketable securities were $678.3 million at June 30, 2026. Revenue for the three months ended June 30, 2026 was $3.7 million versus $19.1 million a year earlier, reflecting lower contributions under the Menarini license and supply arrangements. R&D expenses rose to $41.7 million, SG&A expenses were $26.9 million, and net loss widened to $64.1 million compared with $17.4 million in the prior-year period.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company focused on CETP inhibitor obicetrapib for LDL-C lowering, reported Q2 2026 revenue of $3.7 million, down from $19.1 million as prior Menarini development contributions did not recur and revenue now reflects initial supply sales.
Research and development expenses rose to $41.7 million and selling, general and administrative expenses were $26.9 million, leading to a net loss of $64.1 million, or $0.52 per share; first-half net loss was $112.6 million. Cash, cash equivalents and marketable securities totaled $678.3 million at June 30 2026, with $69.8 million of operating cash outflows in the first half.
Operationally, the EMA’s CHMP issued a positive opinion recommending EU marketing authorization for obicetrapib monotherapy and fixed-dose combination with ezetimibe, with Menarini preparing potential launches in late 2026. The PREVAIL cardiovascular outcomes trial remains underway, with an interim analysis planned in Q4 2026 and a DSMB recommendation expected in Q1 2027.